dc.contributorJunyent, F., Unitat de Farmacologia i Farmacognòsia, Institut de Biomedicina (IBUB), Centros de Investigación Biomédica en Red, Enfermedades Neurodegenerativas (CIBERNED), Facultat de Farmàcia, Universitat de Barcelona, Barcelona, Spain, Unitat de Bioquímica, Facultat de Medicina i Ciències de la Salut, Universitat Rovira i Virgili, Reus, Tarragona, Spain; de Lemos, L., Unitat de Farmacologia i Farmacognòsia, Institut de Biomedicina (IBUB), Centros de Investigación Biomédica en Red, Enfermedades Neurodegenerativas (CIBERNED), Facultat de Farmàcia, Universitat de Barcelona, Barcelona, Spain; Verdaguer, E., Departament de Biologia Cellular, Facultat de Biologia, Universitat de Barcelona, Barcelona, Spain; Pallàs, M., Unitat de Farmacologia i Farmacognòsia, Institut de Biomedicina (IBUB), Centros de Investigación Biomédica en Red, Enfermedades Neurodegenerativas (CIBERNED), Facultat de Farmàcia, Universitat de Barcelona, Barcelona, Spain; Folch, J., Unitat de Bioquímica, Facultat de Medicina i Ciències de la Salut, Universitat Rovira i Virgili, Reus, Tarragona, Spain; Beas-Zárate, C., Departamento de Biología Celular y Molecular, C.U.C.B.A, Universidad de Guadalajara and Division de Neurociencias, Instituto Mexicano del Seguro Social IMSS, Centro de Investigación Biomédica de Occidente (CIBO), Jalisco, Mexico; Camins, A., Unitat de Farmacologia i Farmacognòsia, Institut de Biomedicina (IBUB), Centros de Investigación Biomédica en Red, Enfermedades Neurodegenerativas (CIBERNED), Facultat de Farmàcia, Universitat de Barcelona, Barcelona, Spain; Auladell, C., Departament de Biologia Cellular, Facultat de Biologia, Universitat de Barcelona, Barcelona, Spain
dc.contributorBeas-Zárate, Carlos., Universidad de Guadalajara. Centro Universitario de Ciencias Biológicas y Agropecuarias
dc.creatorJunyent, F.
dc.creatorde Lemos, L.
dc.creatorVerdaguer, E.
dc.creatorPallas, M.
dc.creatorFolch, J.
dc.creatorBeas-Zárate, Carlos
dc.creatorCamins, A.
dc.creatorAuladell, C.
dc.date.accessioned2015-09-15T18:17:10Z
dc.date.accessioned2023-07-04T00:15:37Z
dc.date.available2015-09-15T18:17:10Z
dc.date.available2023-07-04T00:15:37Z
dc.date.created2015-09-15T18:17:10Z
dc.date.issued2012
dc.identifierhttp://www.scopus.com/inward/record.url?eid=2-s2.0-84860898865&partnerID=40&md5=379eba7fd880dfca50dd3a038720215a
dc.identifierhttp://hdl.handle.net/20.500.12104/42477
dc.identifier10.1111/j.1365-2990.2011.01214.x
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/7252936
dc.description.abstractAims: 3-Nitropropionic acid (3-NP) is a toxin that replicates most of the clinical and pathophysiological symptoms of Huntington's disease, inducing neurodegeneration in the striatum due to the inhibition of mitochondrial succinate dehydrogenase. Different pathways have been implicated in the cell death induced by 3-NP in rodents. One of them is the Jun-N-terminal kinase (JNK) pathway, which may play a role in the neurodegenerative process in different diseases. Moreover, the lack of one isoform of JNK (JNK3) has been associated with neuroprotection in different experimental models of neurodegeneration. Therefore, in the present study the role of JNK3 in the experimental Huntington's model induced by 3-NP administration was evaluated. Methods: 3-NP was intraperitoneally administered once a day for 3 days to wild-type and Jnk3-null mice. Coronal brain sections were used to determine cell death and astrogliosis in striatum. Western blots were performed to determine the involvement of different pathways in both wild-type and Jnk3-null mice. Results: Although JNK activation was observed following 3-NP administration, the results indicate that the lack of JNK3 does not confer neuroprotection against 3-NP toxicity. Thus, other pathways must be involved in the neurodegeneration induced in this model. One of the possible pathways towards 3-NP-induced apoptosis could involve the calpains, as their activity was increased in wild-type and Jnk3-null mice. Conclusion: Although JNK3 is a key protein involved in cell death in different neurodegenerative diseases, the present study demonstrates that the lack of JNK3 does not confer neuroprotection against 3-NP-induced neuronal death. © 2011 The Authors. Neuropathology and Applied Neurobiology © 2011 British Neuropathological Society.
dc.relationScopus
dc.relationWOS
dc.relationNeuropathology and Applied Neurobiology
dc.relation38
dc.relation4
dc.relation311
dc.relation321
dc.titleLack of Jun-N-terminal kinase 3 (JNK3) does not protect against neurodegeneration induced by 3-nitropropionic acid
dc.typeArticle


Este ítem pertenece a la siguiente institución